Core Viewpoint - Evolus, Inc. (EOLS) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings per share (EPS) estimated at $0.06, reflecting a 500% increase, and revenues projected at $89.42 million, up 13.3% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to be released on March 3, and the stock price may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Evolus is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.33%, suggesting a bullish outlook from analysts [12]. - However, the stock holds a Zacks Rank of 4, complicating the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Evolus was expected to post a loss of $0.19 per share but delivered a smaller loss of -$0.14, resulting in a positive surprise of +26.32% [13]. - Over the past four quarters, Evolus has only beaten consensus EPS estimates once [14]. Industry Context - Perrigo (PRGO), a peer in the Zacks Medical - Products industry, is expected to report an EPS of $0.8 for the same quarter, indicating a year-over-year decline of 14%, with revenues projected at $1.1 billion, down 3.2% from the previous year [18].

Core Insights - Evolus, Inc. (NASDAQ:EOLS) has had its price target lowered by Mizuho analyst Uy Ear from $19 to $15 while maintaining an Outperform rating, indicating confidence in the company's long-term growth despite a weaker-than-expected fourth quarter [1] - The company reported a revenue of $69 million for the third quarter of 2025, reflecting a 13% year-over-year growth, driven by strong demand for its products Jeuveau and Evolysse [3] - Evolus focuses on injectable aesthetic treatments in the cash-pay market and aims to expand its international presence while building a differentiated portfolio of physician-led brands [4] Financial Performance - The revenue of Evolus for the third quarter of 2025 was $69 million, marking a 13% increase compared to the previous year [3] - The growth is attributed to sustained global demand for Jeuveau and the U.S. launch of Evolysse, showcasing the company's ability to diversify its revenue streams [3] Company Strategy - Evolus is positioning itself for continued market share gains by expanding its product portfolio and international footprint [4] - The company was founded in 2012 and is headquartered in Newport Beach, California, indicating a relatively young but strategically focused operation in the performance beauty sector [4]

Revenue Projections - Preliminary unaudited net revenue for Q4 2025 is expected to be between $88.6 million and $90.6 million, representing a 12% to 15% increase over Q4 2024[4] - Full-year 2025 net revenue is projected to be between $295.5 million and $297.5 million, reflecting an 11% to 12% growth compared to 2024[4] - The company anticipates 2026 net revenue guidance of $327 million to $337 million, indicating an 11% to 13% growth from 2025[4] - The long-term financial outlook for 2028 is updated to reflect total net revenue between $450 million and $500 million, representing a three-year CAGR of 15% to 19%[4] Profitability - Positive non-GAAP operating income for Q4 2025 is reaffirmed at $5 million to $7 million, marking a significant milestone for the company[4] - The company expects to achieve sustainable annual profitability beginning in 2026[9] Product Contributions - Evolysse injectable hyaluronic acid gels contributed approximately 8% of total revenue for full-year 2025[9] - The anticipated commercial launch of Estyme in Europe is expected to enhance revenue contributions in 2026[9] Strategic Focus - The company is focused on increasing market share and expanding its portfolio internationally, with a disciplined spending approach to drive profitability[3] - Cash and cash equivalents as of December 31, 2025, are reported at $53 million, up from $43.5 million on September 30, 2025, indicating strong sales growth and prudent expense management[9]

Core Viewpoint - Evolus, Inc. announced preliminary, unaudited net revenue for Q4 and full-year 2025, indicating a focus on aesthetic portfolio growth [1] Financial Performance - The preliminary unaudited results are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Insights - Evolus Inc. is projected to double in value by 2026 despite recent challenges in consumer sentiment and inflationary pressures affecting demand for elective aesthetic procedures [1] - Mizuho has lowered Evolus's price target to $19 from $20 while maintaining an Outperform rating, reflecting a cautious outlook on the company's product estimates [1][3] Financial Performance - In Q3 2025, Evolus reported global net revenue of $69 million, a 13% year-over-year increase, driven by strong demand for its neurotoxin Jeuveau, which generated $63.2 million [2] - The new Hyaluronic Acid filler, Evolysse, contributed $5.7 million in revenue during the same quarter [2] - For the full year 2025, Evolus revised its total net revenue outlook to between $295 million and $305 million [2] Market Position and Challenges - Evolus holds a 14% market share in the US aesthetic neurotoxin market, supported by a customer loyalty program that has grown to over 1.3 million members, a 34% increase year-over-year [3] - The company added approximately 500 new purchasing accounts in Q3, indicating expansion in its professional customer base [3] - The US aesthetic market is facing challenges, particularly in consumer spending, with the HA filler market experiencing a double-digit decline, complicating Evolysse's market entry [3]

Summary of Evolus Conference Call Company Overview - Evolus is currently in a significant growth phase, having launched its second product, Evolysse, alongside its flagship product Jeuveau, which has established a strong market presence in the U.S. and Europe [2][3][4] Key Points and Arguments Product Development and Market Position - Jeuveau has been recognized as the fastest-growing brand in the U.S. aesthetic market, capturing mid-teens market share, marking the first time a company has achieved double-digit market share since the entry of the first two players [2][4] - Evolysse is positioned as a differentiated product utilizing new technology (COLDEX) for hyaluronic acid (HA) production, with plans to introduce a sculpt product for the mid-face in the upcoming year [3][4][22] - The company has built a customer base of 17,000 clinics across the U.S., which presents significant growth opportunities as it enters the second phase of commercialization [3][4] Market Dynamics and Performance - Despite a challenging macroeconomic environment, Evolus has reported double-digit growth, with Jeuveau continuing to grow in the U.S. and strong international performance, particularly in the U.K. [4][5][48] - The aesthetic market, particularly for neuromodulators, has historically shown resilience during economic downturns, although current conditions are presenting unique challenges [6][7][8] - The company anticipates a rebound in the market, driven by pent-up consumer demand, as consumers are currently delaying treatments due to economic pressures [8][9] Competitive Landscape - The competitive landscape includes established players like AbbVie and Galderma, with Evolus focusing on differentiating its products through quality and innovative marketing strategies [6][7][9] - Evolus has successfully positioned Jeuveau against Botox through head-to-head clinical trials, demonstrating superior efficacy in multiple endpoints [12][13][14] Consumer Trends and Marketing Strategy - There is a growing consumer trend towards preventive aesthetic treatments, with younger demographics increasingly seeking these services [7][8] - Evolus has launched a campaign to rebrand HA fillers, moving away from the term "filler" to "injectable HA," which has resonated positively with consumers [29][30] - The company is leveraging its loyalty program to encourage repeat purchases and cross-selling between Jeuveau and Evolysse [19][22] Financial Outlook and Business Development - Evolus has access to $100 million in capital for business development, with a focus on achieving profitability by the fourth quarter of 2025 and for the full year of 2026 [41][42][48] - The company expects to see sequential improvement in performance as it wraps around a depressed market base, with a strong international growth trajectory anticipated [46][47][48] Future Product Pipeline - The introduction of the Skulpt product is expected in the second half of 2026, which will complement the existing HA product line and enhance the company's market position [46][47] - Evolus is exploring opportunities in biostimulators and other innovative products to expand its portfolio [43][44] Additional Important Insights - The company has successfully reduced expenses by $25 million, positioning itself for profitability amidst a declining market [48] - Evolus is focused on building partnerships with clinics, emphasizing the importance of training and support for product adoption [20][21][25] This summary encapsulates the key insights from the Evolus conference call, highlighting the company's strategic direction, market dynamics, and future growth potential.

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Evolus, Inc. reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +26.32% [1] - The company posted revenues of $68.97 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.70% and showing an increase from $61.08 million year-over-year [2] - Evolus shares have declined approximately 41.9% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, Evolus has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $91.18 million, while for the current fiscal year, it is -$0.48 on revenues of $297.1 million [7] Market Outlook - The company's earnings outlook and management's commentary during the earnings call will be crucial for future stock price movements [3][4] - The Zacks Rank for Evolus is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Products industry, to which Evolus belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8] - Comparatively, ICU Medical, another company in the same industry, is expected to report a quarterly earnings decline of -3.1% year-over-year [9]

Financial Data and Key Metrics Changes - Global net revenue for Q3 2025 was $69 million, representing a 13% increase compared to Q3 2024 [30] - Gross margin for Q3 was reported at 66.5%, with adjusted gross margin at 67.6% [31] - Non-GAAP operating loss for Q3 was $3.1 million, an improvement from a loss of $6.7 million in Q3 2024 [35] Business Line Data and Key Metrics Changes - Jeuveau revenue for Q3 was $63.2 million, while Evolisse contributed $5.7 million [31] - The Evolus consumer loyalty program grew to over 1.3 million members, a 34% increase year-on-year [7] - Evolisse's revenue increased sequentially to approximately $5 million after initial stocking [14] Market Data and Key Metrics Changes - The U.S. aesthetic market remains down in single digits, but Jeuveau outperformed the category with unit volume growth year-to-date [10][12] - The company strengthened its market share to 14% in the U.S. year-to-date [13] Company Strategy and Development Direction - Evolus aims to achieve profitability in 2025 and sustainable annual profitability starting in 2026 [11][37] - The company is focusing on expanding its portfolio and has introduced a bundled offering to drive market share gains [15][56] - Evolus is actively pursuing strategic business development opportunities to expand its pipeline [29] Management's Comments on Operating Environment and Future Outlook - Management noted early signs of stabilization in consumer demand for injectables, despite challenges in the aesthetic market [11] - The company remains confident in navigating potential tariff impacts and maintaining financial performance [18][32] Other Important Information - Evolus submitted a PMA to the U.S. FDA for Evolve's Sculpt, with potential approval anticipated in 2026 [17] - The company has taken proactive measures to mitigate potential tariff impacts on pharmaceuticals, including Jeuveau [18][32] Q&A Session Summary Question: Can you discuss the dynamics of Evolisse and the impact of market sentiment? - Management highlighted that initial training is crucial for product adoption, with significant inflection points observed after second training sessions [44][45] - The market is currently facing challenges, but Q4 is expected to be stronger due to accumulated experience and seasonal factors [48] Question: What are the usage trends between Evolisse Smooth and Form? - Both products are used for the nasolabial fold, but Smooth is preferred for a softer effect while Form provides more structure [57][62] Question: Can you elaborate on the sequential growth for Jeuveau in Q3? - The company maintained consistent promotional efforts and engaged consumers through loyalty programs, which contributed to the growth [66] Question: What is the split between U.S. and international sales for Jeuveau? - The company does not provide detailed segment reporting but noted growth in both U.S. and international markets [71][73] Question: What are the potential impacts of tariffs on the business? - Management is closely monitoring tariff developments and has taken steps to mitigate potential impacts, including pulling forward inventory purchases [103][104]